patients were treated with concurrent chemoradiation followed by brachytherapy. The median follow-up period was 47 months. The three-year DFS and OS were 13.3% and 13.3% respectively.

Conclusion CCCC has a poor prognosis, stage for stage compared to other histologies. The FIGO stage, tumour size, lymphovascular space invasion and pelvic node status were factors that predicted the prognosis. Adjuvant radiotherapy or chemoradiotherapy have a limited role in the treatment of this rare cancer.

Disclosures The authors have no potential conflict of interest to disclose.

285

EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV+ WOMEN OLDER THAN 40 YEARS: SUB-ANALYSIS OF PALOMA CLINICAL TRIAL

¹Yann Gaslain, ²Luis Serrano, ³Andrés Carlos López, ²Silvia González, ⁴Santiago Palacios, ⁵Damian Dexeus, ⁶Pluvio Coronado, ⁷Jesús de la Fuente, ⁸José Antonio López, ⁹Cristina Vanrell. ¹Procure Health; ²Centro Médico Gabinete Velázquez; ³Hospital Quirónsalud; ⁴Instituto Palacios Salud Y Medicina de la Mujer; ⁵Women's Health Institute; ⁶Hospital Clínico San Carlos; ⁷Hospital Universitario Infanta Leonor; ⁸Hospital General Universitario de Alicante; ⁹Hospital de la Santa Creu I Sant Pau

10.1136/ijgc-2020-ESGO.19

Introduction/Background HPV clearance and resolution of cervical HPV-dependent lesions become difficult in peri and postmenopausal women. The objective of this sub-analysis was to evaluate the effect of the Papilocare[®], a multi-ingredient Coriolus versicolor-based vaginal gel, on the normalization of cervical HPV-dependent atypia (ASCUS and LSIL) and associated colposcopic alterations in women older than 40 years.

Methodology Paloma clinical trial (ClinicalTrials.gov NCT04002154) was a multicenter, randomized, open-label, parallel-group, usual practice-controlled clinical trial. Unvaccinated HPV positive women aged between 30–65 with cytology of ASCUS or LSIL and concordant colposcopic image were randomized into 3 groups: A) Papilocare[®] 1 cannula/day for 1 month + 1 cannula/alternate days for 5 months; B) Papilocare[®] 1 cannula/day for 3 months + 1 cannula/alternate days for 3 months; C) Control group: no treatment (usual clinical practice). Primary endpoint: % of patients with normal cytology and concordant colposcopy after 6 months of treatment in the total population, high-risk HPV (16,18,31,33,35,39,45,51,52,56,58,59,68) and very high-risk HPV (patients infected by any combination of 16, 18 and 31) subpopulations. Pap smear evaluations were blind and centrally conducted by an independent researcher at the IECM laboratory (Lugo, Spain). Papilocare[®] arms (A+B) were combined as treatment group.

Results A total of 41 out of 84 evaluated patients included in Paloma trial were older than 40y [mean (SD) age: 47.71 (5.56)], of which 30 and 13 were high-risk HPV and 16-18-31 HPV patients, respectively. At 6 months, normal cytology and concordant colposcopic image was observed in 92%, 90% and 75% of patients treated with Papilocare[®] vs 50%, 33% and 40% of patients in control group, in the total population, and high-risk and 16-18-31 subpopulations (p=0.0066; p=0.0031; p=0.2929, Fisher test) respectively.

Conclusion Papilocare[®] showed a robust efficacy in normalizing cervical HPV lesions in women older than 40 years old, with a statistically significant difference vs control group in the total and high-risk populations.

Disclosures

Funding Procure Health Disclosure: J.Cortés, S.Palacios, D. Dexeus, L. Serrano: Advisory/Consulting Role and Speakers at Procure Health. Y. Gaslain: CEO of Procure Health.

All other authors have declared no conflicts of interest.

287

REAL-LIFE EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV PATIENTS: INTERIM ANALYSIS

¹Yann Gaslain, ²Javier Cortés, ³Javier de Santiago, ⁴María Pilar Sanjuán, ⁵Marta Agenjo, ²Gabriel Fiol, ⁶Carmen García, ⁷Marta Gurrea, ²Perla Hernández. ¹Procure Health; ²Private Practice; ³Centro Oncológico MD Anderson; ⁴Clinica Ginemed; ⁵Hospital Sanitas La Zarzuela; ⁶Hm San Francisco; ⁷Hospital La Fe

10.1136/ijgc-2020-ESGO.20

Introduction/Background Real-life studies inform on the 'effectiveness' of a treatment what is intended to do in routine circumstances. The aim of this study is to evaluate the efficacy of Papilocare[®] - a multi-ingredient Coriolus versicolor-based vaginal gel- on repairing high-risk (HR) HPV-dependent low-degree cervical lesions and HR-HPV clearance in real-life practice.

Methodology Observational, multicenter, prospective, one-cohort study (PAPILOBS study ClinicalTrials.gov: NCT04199260). Currently recruiting 300 vaccinated or not HPV-positive women aged > 25y with Pap smear of ASCUS or LSIL and concordant colposcopy during routine clinical visits in Spain. Patients are treated with Papilocare[®] 1 cannula/day for 21 days the first month + 1 cannula/alternate days for 5 months. After this 6-month period, patients with altered cytology and/or HPV persistency are treated for a 6-month extension treatment period with the same dosage.

Interim analysis of HR-HPV patients with normal Pap smear and concordant colposcopy image (primary endpoint) and patient with HR-HPV cleared (patients with total clearance or partial clearance together with negative Pap smear and normal colposcopy) at 6/12 months is presented. The study was approved by the ethical committee of Public University Hospital of Puerta de Hierro (Madrid). Informed consent was signed by all patients.

Results At 6 months, data of 148 and 146 patients for Pap smear/colposcopy and HR-HPV presence, respectively, were available. 67.6% of patients (100/148) had negative Pap smear and concordant colposcopy. HR-HPV clearance was observed in 58.9% of patients (86/146). Data of 46 and 44 patients included in the 6-month extension treatment period for Pap smear/colposcopy and HR-HPV presence, respectively, were available. At 12 months, 78.3% (36/46) of patients had negative Pap smear and concordant colposcopy and HR-HPV clearance was observed in 70.5% (31/44). Considering all study period, 77% (114/148) and 72.6% (106/146) of patients repaired HR-HPV-dependent cervical lesions and cleared HR-HPV, respectively.

Conclusion In this interim analysis, repairing of HR-HPV-dependent low-degree cervical lesions and clearing HR-HPV, in real life conditions, was achieved after 6-month treatment